rs200475391
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 5P and 1B. PM2PP2PP3_ModerateBS1_Supporting
The NM_004525.3(LRP2):c.11288A>T(p.Glu3763Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000418 in 1,613,246 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.00036 ( 0 hom., cov: 31)
Exomes 𝑓: 0.00042 ( 0 hom. )
Consequence
LRP2
NM_004525.3 missense
NM_004525.3 missense
Scores
12
6
1
Clinical Significance
Conservation
PhyloP100: 8.02
Genes affected
LRP2 (HGNC:6694): (LDL receptor related protein 2) The protein encoded by this gene, low density lipoprotein-related protein 2 (LRP2) or megalin, is a multi-ligand endocytic receptor that is expressed in many different tissues but primarily in absorptive epithilial tissues such as the kidney. This glycoprotein has a large amino-terminal extracellular domain, a single transmembrane domain, and a short carboxy-terminal cytoplasmic tail. The extracellular ligand-binding-domains bind diverse macromolecules including albumin, apolipoproteins B and E, and lipoprotein lipase. The LRP2 protein is critical for the reuptake of numerous ligands, including lipoproteins, sterols, vitamin-binding proteins, and hormones. This protein also has a role in cell-signaling; extracellular ligands include parathyroid horomones and the morphogen sonic hedgehog while cytosolic ligands include MAP kinase scaffold proteins and JNK interacting proteins. Recycling of this membrane receptor is regulated by phosphorylation of its cytoplasmic domain. Mutations in this gene cause Donnai-Barrow syndrome (DBS) and facio-oculoacoustico-renal syndrome (FOAR).[provided by RefSeq, Aug 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), LRP2. . Trascript score misZ 4.5094 (greater than threshold 3.09). GenCC has associacion of gene with intellectual disability, autosomal dominant 40, Stickler syndrome, Donnai-Barrow syndrome.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.923
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.000356 (54/151858) while in subpopulation NFE AF= 0.000706 (48/67984). AF 95% confidence interval is 0.000547. There are 0 homozygotes in gnomad4. There are 24 alleles in male gnomad4 subpopulation. Median coverage is 31. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LRP2 | NM_004525.3 | c.11288A>T | p.Glu3763Val | missense_variant | 59/79 | ENST00000649046.1 | NP_004516.2 | |
LRP2 | XM_011511183.4 | c.11159A>T | p.Glu3720Val | missense_variant | 58/78 | XP_011509485.1 | ||
LRP2 | XM_047444340.1 | c.10364A>T | p.Glu3455Val | missense_variant | 59/79 | XP_047300296.1 | ||
LRP2 | XM_011511184.3 | c.8999A>T | p.Glu3000Val | missense_variant | 44/64 | XP_011509486.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LRP2 | ENST00000649046.1 | c.11288A>T | p.Glu3763Val | missense_variant | 59/79 | NM_004525.3 | ENSP00000496870 | P1 | ||
LRP2 | ENST00000649153.1 | c.2189A>T | p.Glu730Val | missense_variant, NMD_transcript_variant | 11/30 | ENSP00000497617 | ||||
LRP2 | ENST00000650252.1 | c.320A>T | p.Glu107Val | missense_variant, NMD_transcript_variant | 4/24 | ENSP00000496887 |
Frequencies
GnomAD3 genomes AF: 0.000356 AC: 54AN: 151858Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
54
AN:
151858
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000215 AC: 54AN: 251422Hom.: 0 AF XY: 0.000250 AC XY: 34AN XY: 135880
GnomAD3 exomes
AF:
AC:
54
AN:
251422
Hom.:
AF XY:
AC XY:
34
AN XY:
135880
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000424 AC: 620AN: 1461388Hom.: 0 Cov.: 31 AF XY: 0.000436 AC XY: 317AN XY: 727036
GnomAD4 exome
AF:
AC:
620
AN:
1461388
Hom.:
Cov.:
31
AF XY:
AC XY:
317
AN XY:
727036
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000356 AC: 54AN: 151858Hom.: 0 Cov.: 31 AF XY: 0.000324 AC XY: 24AN XY: 74152
GnomAD4 genome
AF:
AC:
54
AN:
151858
Hom.:
Cov.:
31
AF XY:
AC XY:
24
AN XY:
74152
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
2
ALSPAC
AF:
AC:
2
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
5
ExAC
AF:
AC:
29
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 01, 2022 | This sequence change replaces glutamic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 3763 of the LRP2 protein (p.Glu3763Val). This variant is present in population databases (rs200475391, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with LRP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 520735). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LRP2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 22, 2018 | - - |
Donnai-Barrow syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 13, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
DSD incomplete virilization Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Ulrich Schweizer laboratory, Universitaetsklinikum Bonn | Sep 01, 2021 | - - |
LRP2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 19, 2024 | The LRP2 c.11288A>T variant is predicted to result in the amino acid substitution p.Glu3763Val. This variant was reported in one individual with hypoplastic left heart syndrome, but was also observed in two controls (Supp. Table 7 in Theis et al 2020. PubMed ID: 33006316). This variant was also reported in an individual with 46,XY differences of sex development (Marko HL et al 2022. PubMed ID: 34979047). This variant is reported in 0.044% of alleles in individuals of European (non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 03, 2015 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
D;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;M
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
.;D
REVEL
Pathogenic
Sift
Uncertain
.;D
Sift4G
Pathogenic
.;D
Polyphen
D;D
Vest4
0.92
MVP
0.88
MPC
0.95
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at